Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
134
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Ruxu You1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
,
Jinyu Liu2 Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
,
David Bin-Chia Wu3 School of Pharmacy, Monash University Malaysia, Kuala Selangor, Malaysia
,
XinYu Qian4 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
,
Boxiang Lyu5 Machine Learning Department, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA
,
Yu Zhang1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
&
Nan Luo4 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, SingaporeCorrespondence[email protected]
 show all
Pages 10239-10248 | Published online: 05 Dec 2019

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xuan Chen, Zhiguang Yang, Guiyuan Xiang, Lingna Gu, Ziheng Qi, Bin Wan, Yun Lu, Feng Chang & Yumei Zhu. (2022) Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 647-654.
Read now
Yamin Shu, Qilin Zhang, Xucheng He & Li Chen. (2021) Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China. Cancer Management and Research 13, pages 8297-8306.
Read now

Articles from other publishers (9)

Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns & Luis Hernandez. (2024) Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics.
Crossref
Jinxiu Li, Jianmei Yuan, Yong Li, Jian Wang, Daoyin Gong, Qian Xie, Rong Ma, Jiajun Wang, Mihong Ren, Danni Lu & Zhuo Xu. (2022) d-Borneol enhances cisplatin sensitivity via p21/p27-mediated S-phase arrest and cell apoptosis in non-small cell lung cancer cells and a murine xenograft model. Cellular & Molecular Biology Letters 27:1.
Crossref
Ping Chen, Qing Yang, Yinfeng Li, Xiaomei Jing & Jing Chen. (2022) Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy. Frontiers in Oncology 12.
Crossref
Liu Qiao, Zhen Zhou, Xiaohui Zeng & Chongqing Tan. (2021) Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China. Frontiers in Pharmacology 12.
Crossref
Raymond Henderson, Peter Keeling, Declan French, Dave Smart, Richard Sullivan & Mark Lawler. (2021) Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review. Molecular Oncology 15:10, pages 2672-2687.
Crossref
Xiaohui Zeng, Qiao Liu, Liubao Peng, Ye Peng, Lidan Yi, Xia Luo, Sini Li, Xiaomin Wan & Chongqing Tan. (2021) Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Advances in Therapy 38:5, pages 2379-2390.
Crossref
Joyce H. S. You, William C. S. Cho, Wai-kit Ming, Yu-chung Li, Chung-kong Kwan, Kwok-hung Au & Joseph Siu-kie Au. (2021) EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis. PLOS ONE 16:3, pages e0247860.
Crossref
Xiao-Wei Cheng, Wen-Hua Leng & Chun-Ling Mu. (2020) Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients. World Journal of Clinical Cases 8:21, pages 5172-5179.
Crossref
. (2019) Gene-guided afatinib in advanced NSCLC: benefits at high cost. PharmacoEconomics & Outcomes News 843:1, pages 20-20.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.